Ten-year adjuvant hormone therapy for breast cancer: the pros and cons (a review of literature)
Tamoxifen is one of the basic drugs of adjuvant hormone therapy in patients with hormone-dependent breast tumors. The purpose of this paper is to analyze the results of randomized trials of long-term adjuvant hormone therapy for breast cancer.
Main Authors: | S. M. Portnoy, T. A. Shendrikova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2014-07-01
|
Series: | Опухоли женской репродуктивной системы |
Subjects: | |
Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/57 |
Similar Items
-
Breast ductal carcinoma in situ: a literature review of adjuvant hormonal therapy
by: Stephen Kinsey-Trotman, et al.
Published: (2016-12-01) -
Is the extension of adjuvant hormone therapy for breast cancer justified?
by: V. F. Semiglazov, et al.
Published: (2020-07-01) -
Breast cancer hormone receptor levels and benefit from adjuvant tamoxifen in a randomized trial with long-term follow-up
by: Helena Fohlin, et al.
Published: (2024-07-01) -
Adjuvant hormone therapy in postmenopausal patients with locally advanced breast cancer: hope and reality
by: V. I. Borisov
Published: (2014-07-01) -
Tamoxifen in the Management of Breast Cancer: A Case Presented in Multidisciplinary Session With Clinical Discussion and Decision-Making
by: Marziyeh Ghalamkari, et al.
Published: (2019-02-01)